CDK7-IN-2 |
| Catalog No.GC63980 |
CDK7-IN-2 es un potente inhibidor de CDK7. CDK7 estÁ implicado tanto en el control temporal del ciclo celular como en la actividad transcripcional. CDK7 estÁ implicado en el proceso de iniciaciÓn transcripcional mediante la fosforilaciÓn de la subunidad Rbpl de la ARN polimerasa II (RNAPII). CDK7 tiene el potencial para la investigaciÓn de la enfermedad del cÁncer, en particular los cÁnceres agresivos y difÍciles de tratar (extraÍdo de la patente WO2019099298A1, compuesto 1).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2326428-19-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1)[1].
[1]. David Andrew Coates, et al. Compounds useful for inhibiting cdk7. Patent WO2019099298A1.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *